Transformative Impact of Levacetylleucine A-T Treatment in Rare Neurodegenerative Disease

Levacetylleucine A-T treatment has delivered compelling Phase III results, producing statistically significant and clinically meaningful improvements in ataxia severity and daily function for both pediatric and adult patients with ataxia-telangiectasia (A-T). The IntraBio pivotal trial offers real hope for a rare, progressive disease that currently has no approved therapies.

Crossover Design Isolates True Benefit

Investigators used a randomized, placebo-controlled, double-blind crossover protocol followed by an open-label extension, developed in partnership with leading clinicians and A-T patient organizations. Primary assessment relied on the Scale for the Assessment and Rating of Ataxia (SARA), supported by the International Cooperative Ataxia Rating Scale (ICARS) and Investigator’s Clinical Global Impression of Improvement (CGI-I).

Clear Gains Across Multiple Scales

Levacetylleucine A-T treatment reduced mean SARA scores by 1.88 points more than placebo (p<0.001), with parallel advantages on ICARS (−4.22 points, p=0.003) and CGI-I (−0.4 points, p=0.02). No drug-related serious adverse events occurred, confirming a safety profile consistent with previous studies in other neurological disorders.

Regulatory Path and Broader Value

Positive primary and secondary endpoints now support marketing authorization applications to the FDA, EMA, and additional global regulators. Building on its existing approvals for Niemann-Pick disease type C, Levacetylleucine A-T treatment supplies robust, scale-based outcomes data that can strengthen value demonstration and reimbursement discussions for this underserved orphan population.